| 标题 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:The Lancet Oncology 作者:Yi-Long Wu; Ying Cheng; Xiang-Dong Zhou; K. Lee; K. Nakagawa; et al 出版日期:2017-11-01 |
| 求助人 | |
| 下载 |
PDF的下载单位、IP信息已删除
(2025-6-4)